Oculis

Biotechnology ResearchVaud, Switzerland51-200 Employees

Oculis is a global biopharmaceutical company in the biotechnology research sector, headquartered in Lausanne, Switzerland (39 Avenue de la Gare, Vaud 1003). The company maintains a pipeline with several product candidates in development, including OCS-01, a topical eye drop for diabetic macular edema and for inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical anti-TNFα eye drop for dry eye disease and non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis. Oculis is publicly listed on Nasdaq under the ticker OCS and on XICE under the ticker OCS. The organization employs between 51 and 200 people. It operates from Switzerland with additional operations in the United States and Iceland, reflecting its multinational scope.

Sign up for free to view info

Email Format Employee directory